Check out where we have been featuring lately
Petro Terblanche is the managing director of a Afrigen,
Afrigen Biologics and Vaccines is a Cape Town based biotechnology company strategically directed, supported and capitalized by Avacare Healthcare Group and the Industrial Development Corporation (IDC) of South Africa. It was founded in 2014 by Steven G. Reed (PhD) and Erik Iverson (JD, LLM), both of the Infectious Diseases Research Institute (IDRI) www.idri.org in Seattle. Afrigen drives a business strategy focussing on product development, bulk adjuvant manufacturing, and supply and distribution of key biologicals to address unmet healthcare needs. Through international partnerships and local capacity building, Afrigen has established the first ever adjuvant production and formulation technology centre on the African continent. This centre, in partnership with IDRI, a world leader in adjuvant development, focuses on next generation vaccine adjuvants, which are not only geared at preventing disease, but have therapeutic value. These adjuvants confer added potency and durability to vaccines. More recently, Afrigen has ventured into the novel CAM’s space where it aims to bring innovative, differentiated products to market.
MORE ABOUT US
Specialised equipment commonly used in the formulation industry is housed at our R&D laboratories in Cape Town. Afrigen’s highly trained and experienced scientific staff assist with protocol development, validation and analyses. Accurate, reliable and timeous results performed in accordance with GLP principles are provided. Afrigen offers services to collaborators and outside organisations in two key areas:
17
November, 2021Comments